HARTMANN meets 2019 sales and earnings forecast

・ Sales growth of 3.2% (organic 2.8%) mainly driven by Wound Management and KNEIPP 

 ・ EBIT of EUR 104.4 million in line with forecast range shows challenging earnings trend C market effects, regulatory requirements and portfolio alignment measures take their toll 

 ・ Transformation initiated to strengthen HARTMANN for the future C goal: leading position in the European market in core segments 

 ・ Solid financial standing with continued positive net financial position

Britta Fünfstück, Chief Executive Officer of the HARTMANN GROUP: 

“In a challenging market environment, we managed to continue our positive growth path of recent years in 2019. 2019 earnings of the HARTMANN GROUP were in the forecast range but below the prior-year level. Major progress was achieved in the implementation of the new Medical Device Regulation (MDR). We are thus establishing an important basis for our future business and positioning ourselves as a strong partner for our customers. Major product launches were successfully brought to market. And: the 2019 financial year was very much marked by the transformation program of the HARTMANN GROUP.”